Ionis Pharmaceuticals, Inc.IONS
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $1.06B, growing 47.5% year-over-year. TTM net income stood at $-326.98M (28.6% growth). Quarterly EBITDA was $-114.12M and operating income was $-117.42M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze IONS growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters